Nexalin Technology, Inc. ( NXL ) shares surged on Friday afternoon following the announcement of a new patent awarded by the United States Patent and Trademark Office (USPTO). The patent pertains to the company’s Deep Intracranial Frequency Stimulation (DIFS) device, a non-invasive technology designed for the treatment of Alzheimer’s and dementia.

What’s Happening: Nexalin Technology ( NXL ) revealed that the USPTO has granted U.S. Patent No. 12,011,591, covering the company’s advanced DIFS medical device. This device utilizes a proprietary frequency-based waveform to provide deep brain stimulation in a pain-free and undetectable manner, targeting Alzheimer’s and dementia-related brain diseases.

Mark White, CEO of Nexalin Technology ( NXL ), highlighted the significance of this patent in expanding the company’s intellectual property and addressing the growing global dementia treatment market. He noted the substantial market potential, driven by the increasing prevalence of dementia and significant investments in research and development.

What Else: Nexalin’s technology has demonstrated clinical benefits for various neurological conditions, including treatment-resistant depression, migraines, anxiety, insomnia, addiction and PTSD. The new patent underscores the potential of DIFS technology to revolutionize the standard of care for mental health disorders such as Alzheimer’s and dementia.

NXL Price Action: Nexalin Technology ( NXL ) shares were up by 97.3%, trading at $2.15 at the time of writing, according to Benzinga Pro.

See Also: Alphabet Rides on Strong Google Services Segment

Image Via Shutterstock.